Singapore, June 19 -- The Health Sciences Authority received information related to the study titled 'MK-5684-015: A Multicenter, Open-label, Phase 2 Basket Study of MK-5684 in Participants With Selec... Read More
Singapore, June 19 -- The Health Sciences Authority received information related to the study titled 'CA088-1007: A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safet... Read More
Singapore, June 19 -- The Health Sciences Authority received information related to the study titled 'A Multinational, Multicenter, Prospective, Randomized, Controlled, Open-Label, Phase 3 Study of Lu... Read More
Singapore, June 19 -- The Health Sciences Authority received information related to the study titled 'A phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and prel... Read More
Singapore, June 19 -- The Health Sciences Authority received information related to the study titled 'A Phase 1 randomized, double-blind, placebo-controlled, single-ascending-dose study investigating ... Read More
Singapore, June 19 -- The Health Sciences Authority received information related to the study titled 'A Multinational, Multicenter Study With an Open-Label Phase 1b and a Randomized, Double-Blind, Pla... Read More
Singapore, June 19 -- The Health Sciences Authority received information related to the study titled 'A Global, Multicenter, Prospective, Controlled, Open-Label Pivotal Study of Iodofalan (131I) Solut... Read More
Singapore, June 19 -- The Health Sciences Authority received information related to the study titled 'RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib M... Read More
Singapore, June 19 -- The Health Sciences Authority received information related to the study titled 'A Multicenter, Multi-Part, Phase 1/2 Study of EIK1005 as Monotherapy and in Combination with Pembr... Read More
Singapore, June 19 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-controlled, Multicenter, Parallel-group Study to Eval... Read More